U.S. Department of Health and Human Services
Griffin Rodgers

 Contact Info

Tel: 301-496-0001
Email: griffin.rodgers@nih.gov

 Select Experience

  • M.B.A.Johns Hopkins University2005
  • M.D.Brown University1979
  • M.M.Sc.Brown University1979
  • Sc.B.Brown University1976

 Related Links


 Director's Biography

View Dr. Rodgers' Director's Biography.​​

Griffin P. Rodgers, M.D., M.A.C.P.

Director, Office of the Director​
Chief, Molecular and Clinical Hematology Branch
Section Chief, Molecular Hematology Section, Molecular and Clinical Hematology Branch

Specialties: Molecular Biology/Biochemistry, Chemistry/Chemical Biology, Genetics/Genomics, Hematology​​​

Griffin P. Rodgers, M.D., M.A.C.P

Chief, Molecular and Clinical Hematology Branch
Section Chief, Molecular Hematology SectionMolecular and Clinical Hematology Branch
Director, Office of the Director
  • Chemistry/Chemical Biology
  • Genetics/Genomics
  • Hematology
  • Molecular Biology/Biochemistry


Patents, materials, and other research resources appear below. Some resources may be available for use through Material Transfer Agreements (MTAs) or licensing agreements.

Resource Name Description
Rapid method for diagnosing the various forms of alpha-thalassemia (U.S. Patent Number 6,322,981)

The present invention relates to the simultaneous and specific identification of the variant forms of α-thalassemia. This invention utilizes simple and readily available equipment to rapidly identify, diagnose and differentiate the different forms of…

hGC-1, a gene encoding a member of the olfactomedin-related protein family (U.S. Patent Number 7,557,196)

An isolated acid having the sequence of a) SEQ ID NO: 1; b) the sequence of SEQ ID NO: 2; c) the sequence of SEQ ID NO: 3; d) a sequence complementary to any of a), b), or c); or e) a sequence of at least 10 contiguous nucleotides specific for any of…

Simple, rapid and reliable method for detecting thalassemia (U.S. Patent Number 5,281,519)

A simple, rapid and reliable method for diagnosis of thalassemia is described. The method comprises amplification of the cDNA by polymerase chain reaction and determining the ratio between α and β hemoglobin chain mRNAs.

View Additional Research Resources

Clinical Trials

Open studies conducted by NIDDK Principal Investigators appear below that are currently recruiting, not yet recruiting, or available for expanded access.